Publicaciones (40) Publicaciones de JORGE ORTEGA CALVO

2024

  1. Astrocytic GLUT1 reduction paradoxically improves central and peripheral glucose homeostasis

    Science Advances , Vol. 10, Núm. 42

2023

  1. Maternal Immune Activation Induces Cortical Catecholaminergic Hypofunction and Cognitive Impairments in Offspring

    Journal of Neuroimmune Pharmacology, Vol. 18, Núm. 3, pp. 348-365

  2. Peripheral CB1 receptor blockade acts as a memory enhancer through a noradrenergic mechanism

    Neuropsychopharmacology, Vol. 48, Núm. 2, pp. 341-350

  3. Psilozibinaren administrazio akutuaren eraginen ebaluazioa garun kortexean serotonina, noradrenalina eta dopamina mailak neurtuz: garun-mikrodialisiaren bidez burututako ikerlana esna dauden saguetan

    Osasun zientziak: V. Ikergazte Nazioarteko Ikerteta Euskaraz. 2023eko maitzaren 17, 18 eta 19 Donostia, Euskal Herria.

2022

  1. Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response

    Biomedicine and Pharmacotherapy, Vol. 154

2021

  1. Aurresan ezin den Estres Kroniko Moderatua (Chronic Unpredictable Mild Stress, CUMS): depresioaren animalia-eredua

    Osasun zientzak: IV. Ikergazte Nazioarteko Ikerteta Euskaraz. 2021eko ekainaren 9, 10 eta . Gasteiz, Euskal Herria.

  2. Europar Batasunean merkaturatutako SARS-CoV-2 birusaren aurkako txertoen onura/arrisku orekaren ebaluazioa

    Osagaiz: osasun-zientzien aldizkaria, Vol. 5, Núm. 2, pp. 77-96

  3. In Vivo Brain Microdialysis of Monoamines

    Neuromethods (Humana Press Inc.), pp. 489-512

  4. Paliperidone Reversion of Maternal Immune Activation-Induced Changes on Brain Serotonin and Kynurenine Pathways

    Frontiers in Pharmacology, Vol. 12

2020

  1. Terapia antidepresiboaren azken pausoak: oraina eta geroa

    Osagaiz: osasun-zientzien aldizkaria, Vol. 4, Núm. 2, pp. 21-36

2019

  1. Chronic fluoxetine reverses the effects of chronic corticosterone treatment on α2-adrenoceptors in the rat frontal cortex but not locus coeruleus

    Neuropharmacology, Vol. 158

  2. Selective Knockdown of TASK3 Potassium Channel in Monoamine Neurons: a New Therapeutic Approach for Depression

    Molecular Neurobiology, Vol. 56, Núm. 4, pp. 3038-3052

2018

  1. Serotonin 5-HT3 receptor antagonism potentiates the antidepressant activity of citalopram

    Neuropharmacology, Vol. 133, pp. 491-502

  2. Structural and Functional Characterization of the Interaction of Snapin with the Dopamine Transporter: Differential Modulation of Psychostimulant Actions

    Neuropsychopharmacology, Vol. 43, Núm. 5, pp. 1041-1051

2017

  1. Chronic citalopram administration desensitizes prefrontal cortex but not somatodendritic α2-adrenoceptors in rat brain

    Neuropharmacology, Vol. 114, pp. 114

  2. Insomnioaren tratamendu fitoterapeutikoa

    Osagaiz: osasun-zientzien aldizkaria, Vol. 1, Núm. 2, pp. 65-68

2016

  1. Effect of subchronic corticosterone administration on α2-adrenoceptor functionality in rat brain: an in vivo and in vitro study

    Psychopharmacology, Vol. 233, Núm. 23-24, pp. 3861-3867

  2. In vivo brain microdialysis of monoamines

    Neuromethods (Humana Press Inc.), pp. 415-434

2015

  1. Erratum: α2-adrenoceptor antagonists: Synthesis, pharmacological evaluation, and molecular modeling investigation of pyridinoguanidine, pyridino-2-aminoimidazoline and their derivatives (Journal of Medicinal Chemistry (2015) 58 (963-977) DOI: 10.1021/jm501635e)

    Journal of Medicinal Chemistry

  2. α2-adrenoceptor antagonists: Synthesis, pharmacological evaluation, and molecular modeling investigation of pyridinoguanidine, pyridino-2-aminoimidazoline and their derivatives

    Journal of Medicinal Chemistry, Vol. 58, Núm. 2, pp. 963-977